‘The future is challenging us to innovate our delivery methods’: PRA

By Melissa Fassbender contact

- Last updated on GMT

(Image: Frank Lombardi Jr)
(Image: Frank Lombardi Jr)

Related tags: Asia, Japan, Pra health sciences

Biopharmaceutical companies are increasingly relying on CROs in Japan, says an executive with PRA, which recently established a new subsidiary in the country.

“The benefits of operating in Japan certainly outweigh the challenges,”​ said Atsushi Ogawa, president, PRA Japan.

Additionally, the reliance on contract research organizations (CROs) is increasing in Japan, he said, and sponsors have a need for research and development partners. This is due in part to the globalization of the industry, with an increasing number of studies in Japan being multi-national in nature.

Read more:Japan v. China: Becoming two of the largest pharma markets in the world

“Another key benefit of operating in Japan is that we can bring in talented, experienced staff members with valuable expertise in the market,” ​said Ogawa, adding that the country has a motivated workforce who wants to grow and innovate.

In line with this, PRA has offices in the Kansai area, including Osaka, Kyoto, Kobe, and Nara, which Ogawa said are ideal locations for a CRO due to the proximity to pharmaceutical companies, universities, hospitals, and research laboratories.

“The Kansai area also attracts great talent because the commute time is short, land prices are lower, and the transportation network is in place,”​ he added. “The area is a wonderful place to maintain work-life balance.”

Still, the market is challenged by the combination of “high people costs and processes being largely relationship-based,”​ said Ogawa, adding that this means cost per patient is high with any provider.

However, PRA is looking forward, he said, and aims to make Japan a more cost-effective global country to select for trials and Japan-only studies more effective.

“The pharmaceutical R&D landscape is changing, and the future is challenging us to innovate our delivery methods. PRA is leveraging its corporate investments in data and technology to benefit the Japanese market,” ​added Samir Shah, executive vice president and president, strategic solutions at PRA Health Science.

Among the company’s scalable, proprietary solutions moving into the Japanese market are Clinical 6, Symphony, Prism, and Predictivv, Shah told us.

Additionally, PRA late last month announced​ that it has bought out its joint venture with Takeda, thus establishing a new subsidiary based in Japan: PRA Health Sciences K.K.

The addition of Takeda’s staff increases PRA’s totals employee numbers to 450 in Japan, with the opportunity for near term growth – which is occurring rapidly in the country, said Shah.

Related news

Show more

Related products

show more

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Related suppliers

Follow us


View more